For Investors
Immunovant and Health Sciences Acquisitions Corporation hosted a joint conference call to discuss their planned merger. The conference call took place on Friday, October 11, at 8:30am EDT. Following prepared remarks, the call included a question-and-answer session for the investment community.
To listen to the archived webcast, please use this link:
Our Vision
Normal lives for patients with autoimmune diseases
Therapeutic Focus
Autoimmune diseases occur when the immune system is unable to distinguish between harmful pathogens and the body’s own healthy tissues. These diseases target both specific organs and broader bodily systems.
Pipeline
Immunovant’s investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.